Jiangsu Trautec Medical Technology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Jiangsu Trautec Medical Technology Co., Ltd. - overview
Established
2015
Location
Changzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Founded in 2015 and based in Changzhou, China, Jiangsu Trautec Medical Technology Co. , Ltd. operates as a biomedical developer that focuses on recombinant collagen based biomaterials R&D. The company has R & D base and production plant located in Changzhou, Xining and Changsha.
The company cooperates with Chinese University of Hong Kong, Shanghai Changhai Hospital, Shenzhen Bay laboratory Pingshan Center to laboratory and research institute. Jiangxia is the CTO of the company, and the total cost of the project he presided over exceeded HKD 10 million. Haihang Li is the CIO of the company and he participated in the national key research and development plan of the ministry of science and technology - stem cell and transformation research. The company provides recombinant human-derived collagen products.
The business of the company includes the development and production of recombinant collagen-based biomaterials. The company's products include recombinant type I collagen, recombinant type III collagen and recombinant type XVII collagen.
Current Investors
Boyu Capital, Holley Group Co., Ltd, CDH Baifu Capital
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.trautec.com.cn/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.